2019 Symposium
|
2019 Featured Talks » Panel Discussion: Targeting KRASPanel Discussion: Targeting KRAS
Chair: David Cheresh, PhD UC San Diego Moores Cancer Center Peter Olson, PhD, Mirati Therapeutics Yi Liu, PhD, Wellspring Biosciences David Cheresh, PhD David A. Cheresh, PhD, is a leading authority in the study of angiogenesis – the growth of new blood vessels tumors need to grow. Since coming to Moores Cancer Center at UC San Diego Health in 2005, Cheresh has led efforts to develop new collaborations and programs in clinical and basic science with an emphasis on translational medicine. He is Associated Director, Innovation and Industry Alliances, Vice Chair of Pathology, and a Distinguished Professor.
Peter Olson, PhD Pete Olson is the Director of Research at Mirati Therapeutics, a company focused on developing innovative, targeted therapies for the treatment of cancer. Mirati is developing a covalent KRAS G12C inhibitor for the treatment of lung, colon and other KRAS G12C-mutant cancers as well as a spectrum-selective receptor tyrosine kinase inhibitor in combination with a checkpoint inhibitor, for patients who progress on checkpoint inhibitor therapy. Prior to joining Mirati, he was a Senior Group Leader in the Oncology Research Unit at Pfizer.
Yi Liu, PhD Yi Liu, Ph.D., is one of Kura’s co-founders and has served as Chief Scientific Officer since October 2014. Prior to joining Kura, Dr. Liu co-founded and served as Chief Scientific Officer of Wellspring Biosciences Inc., a private biopharmaceutical company, from July 2012 to September 2014. Dr. Liu also co-founded Intellikine, Inc., a private biopharmaceutical company, where he served as Vice President of Drug Discovery from 2007 to May 2012, until its acquisition by Takeda Pharmaceuticals. Prior to Intellikine, Dr. Liu was the head of the drug design group at the Genomics Institute of the Novartis Research Foundation. Earlier in his career, he held senior scientist positions at both SGX Pharmaceuticals, Inc., a public biopharmaceutical company which was acquired by Eli Lilly and Company in 2008, and Curagen Corporation, a public biopharmaceutical development company. Dr. Liu received his Ph.D. in Biochemistry from Princeton University, his MSc in computational chemistry from Beijing University and his BE in Chemical Engineering from Tsinghua University. |